JP2017530694A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530694A5 JP2017530694A5 JP2017509621A JP2017509621A JP2017530694A5 JP 2017530694 A5 JP2017530694 A5 JP 2017530694A5 JP 2017509621 A JP2017509621 A JP 2017509621A JP 2017509621 A JP2017509621 A JP 2017509621A JP 2017530694 A5 JP2017530694 A5 JP 2017530694A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- cells
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 85
- 210000004027 cell Anatomy 0.000 claims 80
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 54
- 108090000765 processed proteins & peptides Proteins 0.000 claims 50
- 229920001184 polypeptide Polymers 0.000 claims 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims 48
- 150000007523 nucleic acids Chemical class 0.000 claims 44
- 108020004707 nucleic acids Proteins 0.000 claims 39
- 102000039446 nucleic acids Human genes 0.000 claims 39
- 230000004048 modification Effects 0.000 claims 29
- 238000012986 modification Methods 0.000 claims 29
- 239000012642 immune effector Substances 0.000 claims 22
- 229940121354 immunomodulator Drugs 0.000 claims 22
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 18
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 18
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 16
- 239000003112 inhibitor Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims 15
- 230000004068 intracellular signaling Effects 0.000 claims 15
- 239000002773 nucleotide Substances 0.000 claims 13
- 125000003729 nucleotide group Chemical group 0.000 claims 13
- 230000011664 signaling Effects 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- -1 CD86 Proteins 0.000 claims 11
- 230000000139 costimulatory effect Effects 0.000 claims 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 102100022339 Integrin alpha-L Human genes 0.000 claims 8
- 230000000779 depleting effect Effects 0.000 claims 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 7
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 7
- 102100025390 Integrin beta-2 Human genes 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 6
- 102100024263 CD160 antigen Human genes 0.000 claims 6
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 6
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims 6
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims 6
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 6
- 102100032818 Integrin alpha-4 Human genes 0.000 claims 6
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 6
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 6
- 102100029197 SLAM family member 6 Human genes 0.000 claims 6
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 6
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims 5
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 5
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 5
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 5
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims 5
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 102100038077 CD226 antigen Human genes 0.000 claims 4
- 102100038078 CD276 antigen Human genes 0.000 claims 4
- 101710185679 CD276 antigen Proteins 0.000 claims 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 4
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims 4
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 claims 4
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 4
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 claims 4
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims 4
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 4
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 claims 4
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 4
- 102100025323 Integrin alpha-1 Human genes 0.000 claims 4
- 102100039904 Integrin alpha-D Human genes 0.000 claims 4
- 102100022341 Integrin alpha-E Human genes 0.000 claims 4
- 102100022338 Integrin alpha-M Human genes 0.000 claims 4
- 102100022297 Integrin alpha-X Human genes 0.000 claims 4
- 102100025304 Integrin beta-1 Human genes 0.000 claims 4
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 4
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims 4
- 102000014128 RANK Ligand Human genes 0.000 claims 4
- 108010025832 RANK Ligand Proteins 0.000 claims 4
- 102100027744 Semaphorin-4D Human genes 0.000 claims 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 3
- 102100027207 CD27 antigen Human genes 0.000 claims 3
- 101150013553 CD40 gene Proteins 0.000 claims 3
- 102100035793 CD83 antigen Human genes 0.000 claims 3
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 3
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 3
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 3
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 3
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 3
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 3
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 3
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
- 102100029198 SLAM family member 7 Human genes 0.000 claims 3
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 3
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 3
- 229940124302 mTOR inhibitor Drugs 0.000 claims 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 2
- 108010056102 CD100 antigen Proteins 0.000 claims 2
- 108010017009 CD11b Antigen Proteins 0.000 claims 2
- 108010065524 CD52 Antigen Proteins 0.000 claims 2
- 108010062802 CD66 antigens Proteins 0.000 claims 2
- 102100027217 CD82 antigen Human genes 0.000 claims 2
- 101710139831 CD82 antigen Proteins 0.000 claims 2
- 102100037904 CD9 antigen Human genes 0.000 claims 2
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 2
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 claims 2
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 claims 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 2
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 claims 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 2
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 claims 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 2
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims 2
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 claims 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 2
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims 2
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims 2
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 claims 2
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 2
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 2
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims 2
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 2
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims 2
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims 2
- 108010041100 Integrin alpha6 Proteins 0.000 claims 2
- 108010030465 Integrin alpha6beta1 Proteins 0.000 claims 2
- 102100033016 Integrin beta-7 Human genes 0.000 claims 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 2
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 2
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 2
- 102000027581 NK cell receptors Human genes 0.000 claims 2
- 108091008877 NK cell receptors Proteins 0.000 claims 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims 2
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims 2
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 2
- 239000012270 PD-1 inhibitor Substances 0.000 claims 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims 2
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 2
- 102100029216 SLAM family member 5 Human genes 0.000 claims 2
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 2
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 2
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000003750 conditioning effect Effects 0.000 claims 2
- 102000003675 cytokine receptors Human genes 0.000 claims 2
- 108010057085 cytokine receptors Proteins 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000001926 lymphatic effect Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims 2
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- 101150051188 Adora2a gene Proteins 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 102100031351 Galectin-9 Human genes 0.000 claims 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims 1
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims 1
- 108010043610 KIR Receptors Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 101100341510 Mus musculus Itgal gene Proteins 0.000 claims 1
- 101100236305 Mus musculus Ly9 gene Proteins 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000006994 Precancerous Conditions Diseases 0.000 claims 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 206010038111 Recurrent cancer Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- SAZUGELZHZOXHB-UHFFFAOYSA-N acecarbromal Chemical compound CCC(Br)(CC)C(=O)NC(=O)NC(C)=O SAZUGELZHZOXHB-UHFFFAOYSA-N 0.000 claims 1
- 208000037832 acute lymphoblastic B-cell leukemia Diseases 0.000 claims 1
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 230000005809 anti-tumor immunity Effects 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 229940126546 immune checkpoint molecule Drugs 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000002434 immunopotentiative effect Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000000174 oncolytic effect Effects 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 230000020509 sex determination Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021121574A JP2021184715A (ja) | 2014-08-19 | 2021-07-26 | 癌処置に使用するための抗ｃｄ１２３キメラ抗原受容体（ｃａｒ） |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014084696 | 2014-08-19 | ||
| CNPCT/CN2014/084696 | 2014-08-19 | ||
| CNPCT/CN2014/090508 | 2014-11-06 | ||
| CN2014090508 | 2014-11-06 | ||
| PCT/US2015/045898 WO2016028896A1 (en) | 2014-08-19 | 2015-08-19 | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021121574A Division JP2021184715A (ja) | 2014-08-19 | 2021-07-26 | 癌処置に使用するための抗ｃｄ１２３キメラ抗原受容体（ｃａｒ） |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2017530694A JP2017530694A (ja) | 2017-10-19 |
| JP2017530694A5 true JP2017530694A5 (enExample) | 2018-09-27 |
| JPWO2016028896A5 JPWO2016028896A5 (enExample) | 2022-02-25 |
| JP7084138B2 JP7084138B2 (ja) | 2022-06-14 |
Family
ID=54011902
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017509621A Active JP7084138B2 (ja) | 2014-08-19 | 2015-08-19 | 癌処置に使用するための抗ｃｄ１２３キメラ抗原受容体（ｃａｒ） |
| JP2021121574A Pending JP2021184715A (ja) | 2014-08-19 | 2021-07-26 | 癌処置に使用するための抗ｃｄ１２３キメラ抗原受容体（ｃａｒ） |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021121574A Pending JP2021184715A (ja) | 2014-08-19 | 2021-07-26 | 癌処置に使用するための抗ｃｄ１２３キメラ抗原受容体（ｃａｒ） |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9815901B2 (enExample) |
| EP (2) | EP3183268B1 (enExample) |
| JP (2) | JP7084138B2 (enExample) |
| KR (1) | KR102616429B1 (enExample) |
| CN (2) | CN107108744B (enExample) |
| AU (2) | AU2015305531B2 (enExample) |
| CA (1) | CA2958553A1 (enExample) |
| CO (1) | CO2017001573A2 (enExample) |
| DK (1) | DK3183268T3 (enExample) |
| ES (1) | ES2791248T3 (enExample) |
| HU (1) | HUE049218T2 (enExample) |
| IL (2) | IL250362B (enExample) |
| LT (1) | LT3183268T (enExample) |
| MX (1) | MX2017002205A (enExample) |
| MY (1) | MY189028A (enExample) |
| PL (1) | PL3183268T3 (enExample) |
| PT (1) | PT3183268T (enExample) |
| RU (2) | RU2020117196A (enExample) |
| SG (1) | SG11201700770PA (enExample) |
| TW (2) | TWI719946B (enExample) |
| WO (1) | WO2016028896A1 (enExample) |
Families Citing this family (225)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| CN104136458A (zh) | 2012-02-22 | 2014-11-05 | 宾夕法尼亚大学董事会 | 在第二代嵌合抗原受体中cd2信号传导结构域的使用 |
| ES2949648T3 (es) | 2012-12-20 | 2023-10-02 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| EP3620473A1 (en) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Novel heterodimeric proteins |
| MX374929B (es) | 2013-02-20 | 2025-03-06 | Novartis Ag | RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO. |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JP2016537345A (ja) | 2013-11-13 | 2016-12-01 | ノバルティス アーゲー | 免疫応答を増強するためのｍＴＯＲ阻害剤 |
| US10640569B2 (en) | 2013-12-19 | 2020-05-05 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| EP4303229A3 (en) | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| KR20230022270A (ko) | 2014-03-28 | 2023-02-14 | 젠코어 인코포레이티드 | Cd38 및 cd3에 결합하는 이중특이적 항체 |
| HUE054588T2 (hu) | 2014-04-07 | 2021-09-28 | Novartis Ag | Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| KR102612313B1 (ko) | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
| US9777061B2 (en) | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| CN107109420A (zh) | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | 使用cll－1嵌合抗原受体的癌症治疗 |
| PL3183268T3 (pl) | 2014-08-19 | 2020-09-07 | Novartis Ag | Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego |
| ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| US20170281624A1 (en) | 2014-09-13 | 2017-10-05 | Novartis Ag | Combination therapies of alk inhibitors |
| WO2016044605A1 (en) | 2014-09-17 | 2016-03-24 | Beatty, Gregory | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| WO2016057705A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| CU24597B1 (es) | 2014-11-26 | 2022-05-11 | Xencor Inc | Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| BR112017011166A2 (pt) | 2014-11-26 | 2018-02-27 | Xencor, Inc. | anticorpos heterodiméricos que se ligam a cd3 e cd38 |
| CN107206025A (zh) | 2014-12-03 | 2017-09-26 | 朱诺治疗学股份有限公司 | 用于过继细胞治疗的方法和组合物 |
| US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| CA2972597A1 (en) | 2014-12-29 | 2016-07-07 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| EP3270936A4 (en) | 2015-03-17 | 2018-08-08 | Chimera Bioengineering Inc. | Smart car devices, de car polypeptides, side cars and uses thereof |
| CN119925616A (zh) | 2015-04-08 | 2025-05-06 | 诺华股份有限公司 | Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法 |
| ES2948133T3 (es) | 2015-04-17 | 2023-08-31 | Novartis Ag | Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico |
| US12128069B2 (en) | 2015-04-23 | 2024-10-29 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| WO2016185443A1 (en) | 2015-05-20 | 2016-11-24 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
| CN107849112B (zh) * | 2015-06-25 | 2022-04-01 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| TWI859112B (zh) | 2015-07-21 | 2024-10-21 | 瑞士商諾華公司 | 改良免疫細胞之功效及擴展之方法 |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| JP6905163B2 (ja) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
| CA3004738A1 (en) * | 2015-11-09 | 2017-05-18 | Aperisys, Inc. | Modified immune cells and uses thereof |
| MA43380A (fr) | 2015-12-03 | 2018-10-10 | Juno Therapeutics Inc | Récepteurs chimériques modifiés et compositions et procédés associés |
| CA3006432A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| US10227410B2 (en) | 2015-12-07 | 2019-03-12 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
| US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| CN109069597A (zh) | 2015-12-22 | 2018-12-21 | 诺华股份有限公司 | 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗 |
| EP3397755B1 (en) | 2015-12-28 | 2024-11-06 | Novartis AG | Methods of making chimeric antigen receptor -expressing cells |
| MX2018008106A (es) | 2015-12-30 | 2019-03-14 | Novartis Ag | Terapias con celulas inmunoefectoras de una eficacia mejorada. |
| EP3423482A1 (en) | 2016-03-04 | 2019-01-09 | Novartis AG | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
| WO2017177149A2 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2017180565A1 (en) * | 2016-04-14 | 2017-10-19 | Immunomedics, Inc. | Combination therapy with anti-hla-dr antibodies and kinase inhibitors in hematopoietic cancers |
| PL3443096T3 (pl) | 2016-04-15 | 2023-06-19 | Novartis Ag | Kompozycje i sposoby do selektywnej ekspresji chimerycznych receptorów antygenowych |
| EP3458077A4 (en) | 2016-05-17 | 2020-04-01 | Chimera Bioengineering Inc. | METHODS OF MANUFACTURING NEW AREAS OF ANTIGEN BINDING |
| US11191771B2 (en) | 2016-06-09 | 2021-12-07 | Seagen Inc. | Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors |
| US10787518B2 (en) | 2016-06-14 | 2020-09-29 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| EP4353750A3 (en) * | 2016-06-24 | 2024-07-24 | iCell Gene Therapeutics LLC | Chimeric antigen receptors (cars), compositions and methods thereof |
| EP4050032A1 (en) | 2016-06-28 | 2022-08-31 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| AU2017295886C1 (en) | 2016-07-15 | 2024-05-16 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| WO2018017928A1 (en) * | 2016-07-22 | 2018-01-25 | Seattle Genetics, Inc. | Combination therapy using a cd19-adc and rchp |
| KR20190038567A (ko) * | 2016-07-26 | 2019-04-08 | 테사 테라퓨틱스 피티이. 엘티디. | 키메라 항원 수용체 |
| TW202508628A (zh) * | 2016-07-28 | 2025-03-01 | 瑞士商諾華公司 | 嵌合抗原受體及pd-1抑制劑之組合療法 |
| RU2019105693A (ru) * | 2016-08-01 | 2020-09-01 | Новартис Аг | Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CN107793481A (zh) * | 2016-08-31 | 2018-03-13 | 南京传奇生物科技有限公司 | 一种靶向人cd123的嵌合受体配体及其应用 |
| CN112481217A (zh) | 2016-09-01 | 2021-03-12 | 嵌合体生物工程公司 | Gold优化的car t-细胞 |
| US20190209652A1 (en) * | 2016-09-23 | 2019-07-11 | Oncosec Medical Incorporated | Modulating responses to checkpoint inhibitor therapy |
| CN109844126A (zh) | 2016-09-28 | 2019-06-04 | 诺华股份有限公司 | 基于多孔膜的大分子递送系统 |
| EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
| KR102562519B1 (ko) | 2016-10-14 | 2023-08-02 | 젠코어 인코포레이티드 | IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질 |
| JP7222888B2 (ja) * | 2016-11-16 | 2023-02-15 | アブリンクス エン．ヴェー． | Ｃｄ１２３及びｔｃｒアルファ／ベータに結合することが可能なｔ細胞動員ポリペプチド |
| CA3044355A1 (en) | 2016-11-23 | 2018-05-31 | Novartis Ag | Methods of enhancing immune response with everolimus, dactolisib or both |
| KR20190104528A (ko) | 2016-12-03 | 2019-09-10 | 주노 쎄러퓨티크스 인코퍼레이티드 | Car-t 세포들 투여를 결정하는 방법 |
| MA46998A (fr) | 2016-12-05 | 2019-10-09 | Juno Therapeutics Inc | Production de cellules modifiées pour une thérapie cellulaire adoptive |
| CN107058390A (zh) * | 2017-01-17 | 2017-08-18 | 上海交通大学医学院附属第九人民医院 | 一种慢病毒载体、重组慢病毒质粒、病毒及病毒的应用 |
| EP3570850A4 (en) * | 2017-01-18 | 2020-10-14 | Thalia Papayannopoulou | PACKAGING COMPOSITIONS AND METHODS FOR A TRANSPLANT RECEIVER |
| EP3574005B1 (en) | 2017-01-26 | 2021-12-15 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| ES2988795T3 (es) | 2017-02-27 | 2024-11-21 | Juno Therapeutics Inc | Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| SG11201907434RA (en) | 2017-03-22 | 2019-10-30 | Novartis Ag | Compositions and methods for immunooncology |
| US11104737B2 (en) | 2017-03-28 | 2021-08-31 | Rigel Pharmaceuticals, Inc. | ACVR2A-specific antibody and method of treatment of muscle atrophy |
| CN118161496A (zh) | 2017-03-31 | 2024-06-11 | 小利兰·斯坦福大学托管委员会 | 通过抑制或调节t细胞受体信号传导来治疗t细胞耗竭的方法 |
| JP2020517259A (ja) | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| WO2018213337A1 (en) | 2017-05-15 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
| CA3065929A1 (en) * | 2017-06-01 | 2018-12-06 | Michael Wayne SAVILLE | Bispecific antibodies that bind cd123 and cd3 |
| CN111225675B (zh) * | 2017-06-02 | 2024-05-03 | 朱诺治疗学股份有限公司 | 使用过继细胞疗法治疗的制品和方法 |
| US11434290B2 (en) | 2017-06-08 | 2022-09-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chimeric antigen receptors with enhanced NFκB signaling |
| JP2020524512A (ja) | 2017-06-21 | 2020-08-20 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法 |
| EP3645122A1 (en) | 2017-06-30 | 2020-05-06 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains |
| WO2019018525A1 (en) * | 2017-07-20 | 2019-01-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CHIMERIC ANTIGENIC RECEPTORS BINDING TO CD123 |
| CN109423495A (zh) * | 2017-08-24 | 2019-03-05 | 上海恒润达生生物科技有限公司 | 一种双靶向嵌合抗原受体及其用途 |
| JP2021500859A (ja) * | 2017-09-22 | 2021-01-14 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | Ｎｆｋｂシグナル伝達の増強を伴うキメラ抗原受容体 |
| US11559549B2 (en) | 2017-09-26 | 2023-01-24 | Longwood University | PD1-specific chimeric antigen receptor as an immunotherapy |
| WO2019072824A1 (en) * | 2017-10-09 | 2019-04-18 | Cellectis | IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES |
| SG11202003415XA (en) | 2017-10-18 | 2020-05-28 | Novartis Ag | Compositions and methods for selective protein degradation |
| CN109694854B (zh) * | 2017-10-20 | 2023-11-21 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| KR20200069358A (ko) | 2017-10-25 | 2020-06-16 | 노파르티스 아게 | 키메라 항원 수용체 발현 세포의 제조 방법 |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| PL3704230T3 (pl) | 2017-11-01 | 2025-02-24 | Juno Therapeutics, Inc. | Proces wytwarzania kompozycji terapeutycznych z komórek zmodyfikowanych genetycznie |
| CN112272563A (zh) | 2017-11-08 | 2021-01-26 | Xencor股份有限公司 | 使用新颖抗pd-1序列的双特异性和单特异性抗体 |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| MX2020005651A (es) * | 2017-11-30 | 2020-10-28 | Novartis Ag | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. |
| KR20200116081A (ko) | 2017-12-01 | 2020-10-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | 유전자 조작된 세포의 투약 및 조절 방법 |
| KR20250141843A (ko) | 2017-12-08 | 2025-09-29 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 요법을 위한 표현형 마커 및 관련 방법 |
| MX2020006322A (es) | 2017-12-19 | 2020-09-18 | Xencor Inc | Proteinas de fusion il-2 fc modificadas. |
| JP7394058B2 (ja) * | 2017-12-21 | 2023-12-07 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規抗原結合部分の特異性試験のためのユニバーサルレポーター細胞アッセイ |
| CN111492243B (zh) * | 2017-12-21 | 2024-11-01 | 豪夫迈·罗氏有限公司 | 用于新颖抗原结合模块的特异性测试的car-t细胞测定法 |
| CN111542547B (zh) * | 2018-01-04 | 2024-02-13 | 美天施生物科技有限两合公司 | 对bdca2抗原具有特异性的嵌合抗原受体 |
| TW201940182A (zh) | 2018-01-22 | 2019-10-16 | 美商安德賽特公司 | Car t 細胞之使用方法 |
| CA3090089A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CN111989108B (zh) | 2018-02-13 | 2024-07-16 | 嵌合体生物工程公司 | 利用rna去稳定元件协调基因表达 |
| US12473336B2 (en) | 2018-02-21 | 2025-11-18 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses thereof |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| EP3759491A1 (en) * | 2018-03-01 | 2021-01-06 | H. Hoffnabb-La Roche Ag | Specificity assay for novel target antigen binding moieties |
| WO2019183094A1 (en) * | 2018-03-19 | 2019-09-26 | The Regents Of The University Of Michigan | Compositions and methods for t-cell and cytokine activation |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| AU2019249215A1 (en) | 2018-04-06 | 2020-10-22 | The Regents Of The University Of California | Methods of treating EGFRvIII expressing glioblastomas |
| EP3773633A4 (en) | 2018-04-06 | 2022-01-26 | The Regents of The University of California | METHODS OF TREATMENT OF GLIOBLASTOMA |
| AU2019256539A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
| CA3097741A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| EP3802825A1 (en) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CA3100724A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof |
| EP3817767A1 (en) * | 2018-07-02 | 2021-05-12 | Cellectis | Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| TWI841576B (zh) * | 2018-07-13 | 2024-05-11 | 大陸商南京傳奇生物科技有限公司 | 用於治療傳染病之共受體系統 |
| EP3831936A4 (en) | 2018-07-31 | 2022-04-13 | Thyas Co. Ltd. | METHOD FOR PRODUCING A REGENERATED T LYMPHOCYTE POPULATION USING IPS CELLS |
| KR20210040992A (ko) * | 2018-08-01 | 2021-04-14 | 난트케이웨스트, 인크. | 검증된 표적에 대한 2차 귀소 활성화를 갖는 케모카인 반응성 활성화된 자연 살해 세포 |
| CN119752803A (zh) * | 2018-08-01 | 2025-04-04 | 南克维斯特公司 | 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统 |
| EP3844265A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| TW202538050A (zh) | 2018-08-31 | 2025-10-01 | 瑞士商諾華公司 | 製備表現嵌合抗原受體的細胞之方法 |
| AU2019337603A1 (en) * | 2018-09-13 | 2021-05-13 | Nkarta, Inc. | Natural killer cell compositions and immunotherapy methods for treating tumors |
| AU2019344795A1 (en) * | 2018-09-17 | 2021-03-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors targeting CD19 and CD20 and their uses |
| CN113260630B (zh) * | 2018-09-20 | 2024-05-24 | 莱蒂恩技术公司 | 用于用抗cd123免疫治疗来治疗癌症的组合物和方法 |
| CN110950954B (zh) * | 2018-09-26 | 2021-06-25 | 重庆精准生物技术有限公司 | 抗cd123人源化单链抗体及其应用 |
| WO2020072821A2 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12257286B2 (en) | 2018-10-31 | 2025-03-25 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN109754394B (zh) * | 2018-12-28 | 2021-02-23 | 上海联影智能医疗科技有限公司 | 三维医学图像处理装置及方法 |
| WO2020125806A1 (en) | 2018-12-17 | 2020-06-25 | Shanghai United Imaging Intelligence Co., Ltd. | Systems and methods for image segmentation |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN109777783B (zh) * | 2019-02-20 | 2023-07-04 | 上海尚泰生物技术有限公司 | 表达cxcr2的car-nk92细胞、制备方法及其应用 |
| WO2020172553A1 (en) | 2019-02-22 | 2020-08-27 | Novartis Ag | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
| CA3126087A1 (en) | 2019-02-25 | 2020-09-03 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| EP3930850A1 (en) | 2019-03-01 | 2022-01-05 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| WO2020198678A1 (en) * | 2019-03-27 | 2020-10-01 | University Of Virginia Patent Foundation | Priming with targeted activated t cells can enhance chemo responsiveness of cancer cells |
| US20220160771A1 (en) | 2019-04-10 | 2022-05-26 | Iulia Diaconu | Flt3-specific chimeric antigen receptors and methods of using the same |
| WO2020210665A1 (en) * | 2019-04-12 | 2020-10-15 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with cd20 safety switch |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
| AU2020263495B2 (en) * | 2019-04-26 | 2025-09-25 | Allogene Therapeutics, Inc. | Rituximab-resistant chimeric antigen receptors and uses thereof |
| WO2020227071A1 (en) | 2019-05-04 | 2020-11-12 | Inhibrx, Inc. | Cd123-binding polypeptides and uses thereof |
| CN120775051A (zh) | 2019-05-21 | 2025-10-14 | 诺华股份有限公司 | Cd19结合分子及其用途 |
| WO2020251046A1 (ja) | 2019-06-14 | 2020-12-17 | サイアス株式会社 | 医薬組成物 |
| CN114786686A (zh) | 2019-08-18 | 2022-07-22 | 嵌合体生物工程公司 | Gold控制的转基因的联合疗法 |
| JP2022546364A (ja) * | 2019-08-27 | 2022-11-04 | ヤンセン バイオテツク，インコーポレーテツド | キメラ抗原受容体系及びその使用 |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| AR120430A1 (es) | 2019-11-08 | 2022-02-16 | Humanigen Inc | Células car-t dirigidas a epha3 para el tratamiento de tumores |
| AU2020394441B2 (en) | 2019-11-26 | 2025-11-13 | Novartis Ag | CD19 and CD22 chimeric antigen receptors and uses thereof |
| IL293215A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors that bind bcma and cd19 and their uses |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| BR112022011902A2 (pt) | 2019-12-20 | 2022-09-06 | Novartis Ag | Terapias de combinação |
| AU2021208642B2 (en) * | 2020-01-17 | 2025-06-05 | Immunelogic Therapeutics, Inc. | Pro-antibody that reduces off-target toxicity |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| TW202146441A (zh) | 2020-02-27 | 2021-12-16 | 瑞士商諾華公司 | 製備表現嵌合抗原受體的細胞之方法 |
| CA3173737A1 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20210277149A1 (en) * | 2020-03-06 | 2021-09-09 | Mustang Bio, Inc. | Anti-idiotype antibodies and methods of using the same |
| CN113493522B (zh) * | 2020-04-03 | 2023-04-28 | 重庆精准生物技术有限公司 | 双特异性嵌合抗原受体及其应用 |
| CN113493521B (zh) * | 2020-04-03 | 2023-05-05 | 重庆精准生物技术有限公司 | 靶向cd19和cd123的双靶点嵌合抗原受体及其应用 |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| CN115917317A (zh) | 2020-06-08 | 2023-04-04 | 詹森生物科技公司 | 用于测定表达嵌合抗原的免疫细胞的体外肿瘤杀伤活性的基于细胞的测定法 |
| US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| CN116813777A (zh) | 2020-06-22 | 2023-09-29 | 恩格姆生物制药公司 | Lair-1结合剂及其使用方法 |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| AU2021305084A1 (en) | 2020-07-07 | 2023-02-02 | Cancure, Llc | MIC antibodies and binding agents and methods of using the same |
| CN116134027B (zh) | 2020-08-03 | 2025-01-24 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| CN111995688B (zh) * | 2020-08-13 | 2024-01-16 | 金鑫 | 靶向cd123和nkg2d配体的双特异嵌合抗原受体及应用 |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| CA3188867A1 (en) * | 2020-08-20 | 2022-02-24 | Xueyin Wang | Compositions and methods for treating ceacam positive cancers |
| US20230302155A1 (en) | 2020-08-21 | 2023-09-28 | Novartis Ag | Compositions and methods for in vivo generation of car expressing cells |
| JP2023549140A (ja) | 2020-11-04 | 2023-11-22 | マイエロイド・セラピューティクス，インコーポレーテッド | 操作されたキメラ融合タンパク質組成物およびその使用方法 |
| EP4243857A1 (en) | 2020-11-13 | 2023-09-20 | Novartis AG | Combination therapies with chimeric antigen receptor (car)-expressing cells |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| WO2022161355A1 (en) | 2021-01-26 | 2022-08-04 | Cytocares (Shanghai) Inc. | Chimeric antigen receptor (car) constructs and nk cells expressing car constructs |
| CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体 |
| AU2022237618A1 (en) | 2021-03-17 | 2023-10-12 | Create Medicines, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| US20240384293A1 (en) | 2021-04-27 | 2024-11-21 | Novartis Ag | Viral vector production system |
| WO2022241029A1 (en) | 2021-05-11 | 2022-11-17 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| JP7692226B2 (ja) | 2021-05-25 | 2025-06-13 | ヴァクセル－バイオ | モノボディベースのキメラ抗原受容体及びそれを含む免疫細胞 |
| WO2022267843A1 (en) * | 2021-06-21 | 2022-12-29 | Westlake University | Library construction method based on long overhang sequence ligation |
| EP4376877A2 (en) * | 2021-07-29 | 2024-06-05 | Vor Biopharma Inc. | Chimeric antigen receptors for treatment of cancer |
| CN114933654B (zh) * | 2021-08-16 | 2024-09-06 | 上海优替济生生物医药有限公司 | 靶向cd123的抗体、嵌合抗原受体及其用途 |
| US20250000973A1 (en) | 2021-08-20 | 2025-01-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20230338424A1 (en) * | 2022-03-02 | 2023-10-26 | Lentigen Technology, Inc. | Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| CN120112650A (zh) | 2022-10-26 | 2025-06-06 | 诺华股份有限公司 | 慢病毒配制品 |
| WO2024094004A1 (zh) * | 2022-11-03 | 2024-05-10 | 重庆精准生物技术有限公司 | 靶向cd123的全人源抗体及其应用 |
| WO2024151831A2 (en) * | 2023-01-12 | 2024-07-18 | University Of Virginia Patent Foundation | Anti-cith3 antibodies and uses thereof |
| CN116836282B (zh) * | 2023-02-13 | 2024-03-29 | 北京艺妙神州医药科技有限公司 | 抗体、嵌合抗原受体及其用途 |
| AU2024276994A1 (en) | 2023-05-24 | 2025-10-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| CN116990504B (zh) * | 2023-09-27 | 2023-12-01 | 苏州旭光科星抗体生物科技有限公司 | 检测人可溶性cd4的双抗体夹心酶联免疫试剂盒 |
Family Cites Families (410)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US4433059A (en) | 1981-09-08 | 1984-02-21 | Ortho Diagnostic Systems Inc. | Double antibody conjugate |
| US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| DE3381783D1 (de) | 1982-03-03 | 1990-09-13 | Genentech Inc | Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| JPH021556A (ja) | 1988-06-09 | 1990-01-05 | Snow Brand Milk Prod Co Ltd | ハイブリッド抗体及びその作製方法 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| AU6290090A (en) | 1989-08-29 | 1991-04-08 | University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5273743A (en) | 1990-03-09 | 1993-12-28 | Hybritech Incorporated | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9012995D0 (en) | 1990-06-11 | 1990-08-01 | Celltech Ltd | Multivalent antigen-binding proteins |
| JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| ATE145428T1 (de) | 1990-12-14 | 1996-12-15 | Cell Genesys Inc | Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| EP1279731B1 (en) | 1991-03-01 | 2007-05-30 | Dyax Corporation | Process for the development of binding mini-proteins |
| US7049136B2 (en) | 1991-03-07 | 2006-05-23 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| NZ241855A (en) | 1991-03-07 | 1994-04-27 | Gen Hospital Corp | Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor |
| US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
| ES2315612T3 (es) | 1991-04-10 | 2009-04-01 | The Scripps Research Institute | Genotecas de receptores heterodimericos usando fagemidos. |
| EP0509826A1 (en) | 1991-04-19 | 1992-10-21 | Schering Corporation | Subunit of the human interleukin 3 receptor |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| US6511663B1 (en) | 1991-06-11 | 2003-01-28 | Celltech R&D Limited | Tri- and tetra-valent monospecific antigen-binding proteins |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
| DK0654085T3 (da) | 1992-01-23 | 1997-09-22 | Merck Patent Gmbh | Monomere og dimere antistof-fragment-fusionsproteiner |
| ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| AU675223B2 (en) | 1992-05-08 | 1997-01-30 | Creative Biomolecules, Inc. | Chimeric multivalent protein analogues and methods of use thereof |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| EP0672068A4 (en) | 1992-09-25 | 1997-02-26 | Commw Scient Ind Res Org | TARGET MOLECULES BINDING POLYPEPTIDES. |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| GB9323648D0 (en) | 1992-11-23 | 1994-01-05 | Zeneca Ltd | Proteins |
| DE69329974T2 (de) | 1992-12-04 | 2001-07-19 | Medical Research Council, London | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US7211259B1 (en) | 1993-05-07 | 2007-05-01 | Immunex Corporation | 4-1BB polypeptides and DNA encoding 4-1BB polypeptides |
| US6476198B1 (en) | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
| US5635602A (en) | 1993-08-13 | 1997-06-03 | The Regents Of The University Of California | Design and synthesis of bispecific DNA-antibody conjugates |
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| WO1995014023A1 (en) | 1993-11-19 | 1995-05-26 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| ATE191218T1 (de) | 1993-12-17 | 2000-04-15 | Novartis Ag | Rapamycin-derivate als immunosuppressoren |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| DE69528894T2 (de) | 1994-05-02 | 2003-03-27 | Bernd Groner | Bifunktionelles protein, herstellung und verwendung |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| WO1996013583A2 (en) | 1994-10-20 | 1996-05-09 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Targeted hetero-association of recombinant proteins to multi-functional complexes |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US6103521A (en) | 1995-02-06 | 2000-08-15 | Cell Genesys, Inc. | Multispecific chimeric receptors |
| HU225688B1 (en) | 1995-02-24 | 2007-06-28 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| CA2222055A1 (en) | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Multimeric proteins |
| PL184731B1 (pl) | 1995-06-09 | 2002-12-31 | Novartis Ag | Pochodne rapamycyny, zastosowanie pochodnych rapamycyny i kompozycja farmaceutyczna |
| FR2736550B1 (fr) | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
| AU6873396A (en) | 1995-10-16 | 1997-05-07 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| US6177078B1 (en) | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
| US5874240A (en) | 1996-03-15 | 1999-02-23 | Human Genome Sciences, Inc. | Human 4-1BB receptor splicing variant |
| WO1997038102A1 (en) | 1996-04-04 | 1997-10-16 | Unilever Plc | Multivalent and multispecific antigen-binding protein |
| EP0937082A2 (en) | 1996-07-12 | 1999-08-25 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| JP4440344B2 (ja) | 1996-08-16 | 2010-03-24 | シェーリング コーポレイション | 哺乳動物細胞表面抗原；関連試薬 |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| EP0937095A4 (en) | 1996-10-25 | 1999-12-22 | Cell Genesys Inc | TARGETED CYTOLYSIS OF CANCER CELLS |
| EP1712623B1 (en) | 1997-01-21 | 2011-10-19 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| CA2288992C (en) | 1997-04-30 | 2012-06-12 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| CA2304254C (en) | 1997-06-11 | 2012-05-22 | Hans Christian Thogersen | Trimerising module |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US20030060444A1 (en) | 1997-06-25 | 2003-03-27 | Celltech Therapeutics, Ltd. | Cell activation process and reagents therefor |
| GB9713473D0 (en) | 1997-06-25 | 1997-09-03 | Celltech Therapeutics Ltd | Biological products |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| TW557297B (en) | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
| CA2308114A1 (en) | 1997-10-21 | 1999-04-29 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
| ATE461282T1 (de) | 1997-10-27 | 2010-04-15 | Bac Ip Bv | Multivalente antigenbindende proteine |
| CA2317727C (en) | 1998-01-23 | 2013-01-08 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Multipurpose antibody derivatives |
| IL137409A0 (en) | 1998-02-09 | 2001-07-24 | Genentech Inc | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
| HUP9900956A2 (hu) | 1998-04-09 | 2002-04-29 | Aventis Pharma Deutschland Gmbh. | Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk |
| DE69925909T2 (de) | 1998-04-15 | 2006-05-11 | Brigham & Women's Hospital, Inc., Boston | T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| GB9809658D0 (en) | 1998-05-06 | 1998-07-01 | Celltech Therapeutics Ltd | Biological products |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| ES2207278T3 (es) | 1998-07-28 | 2004-05-16 | Micromet Ag | Heterominicuerpos. |
| CA2343156A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| US7052906B1 (en) | 1999-04-16 | 2006-05-30 | Celltech R & D Limited | Synthetic transmembrane components |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| EP1196186B1 (en) | 1999-07-12 | 2007-10-31 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| EP1212331B1 (en) | 1999-08-24 | 2004-04-21 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9925848D0 (en) | 1999-11-01 | 1999-12-29 | Celltech Therapeutics Ltd | Biological products |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| ES2302726T3 (es) | 2000-02-24 | 2008-08-01 | Invitrogen Corporation | Estimulacion y concentracion simultanea de celulas. |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| EP1263463B1 (en) | 2000-03-06 | 2011-05-25 | University of Kentucky Research Foundation | Use of an antibody or an immunotoxin that selectively binds to cd123 to impair hematologic cancer progenitor cells |
| HUP0300369A2 (hu) | 2000-04-11 | 2003-06-28 | Genentech, Inc. | Többértékű antitestek és alkalmazásuk |
| AU2001264946A1 (en) | 2000-05-24 | 2001-12-03 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| IL136511A0 (en) | 2000-06-01 | 2001-06-14 | Gavish Galilee Bio Appl Ltd | Genetically engineered mhc molecules |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| WO2002002781A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| CN1461344A (zh) | 2000-07-25 | 2003-12-10 | 免疫医疗公司 | 多价靶结合蛋白 |
| GB0025307D0 (en) | 2000-10-16 | 2000-11-29 | Celltech Chiroscience Ltd | Biological products |
| CN1308447C (zh) | 2000-10-20 | 2007-04-04 | 中外制药株式会社 | 低分子化的激动剂抗体 |
| US7229960B2 (en) * | 2000-11-03 | 2007-06-12 | University Of Vermont And State Agricultural College | Methods and compositions for inhibiting GRB7 |
| AU2001297703B2 (en) | 2000-11-07 | 2006-10-19 | City Of Hope | CD19-specific redirected immune cells |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| WO2002072635A2 (en) | 2001-03-13 | 2002-09-19 | University College London | Specific binding members |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| CA2445746C (en) | 2001-04-30 | 2012-09-18 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| ATE477280T1 (de) | 2001-06-28 | 2010-08-15 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| PT1419179E (pt) | 2001-08-10 | 2010-03-16 | Univ Aberdeen | Domínios de ligação de antigenes |
| DE60124912T2 (de) | 2001-09-14 | 2007-06-14 | Affimed Therapeutics Ag | Multimerische, einzelkettige, Tandem-Fv-Antikörper |
| US20030186374A1 (en) | 2001-10-01 | 2003-10-02 | Hufton Simon E. | Multi-chain eukaryotic display vectors and uses thereof |
| US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| WO2003049684A2 (en) | 2001-12-07 | 2003-06-19 | Centocor, Inc. | Pseudo-antibody constructs |
| US7638326B2 (en) | 2002-01-03 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform |
| WO2003057171A2 (en) | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| CN100522967C (zh) | 2002-02-01 | 2009-08-05 | 阿里亚德基因治疗公司 | 含磷化合物及其应用 |
| CA2478011C (en) | 2002-03-01 | 2013-05-21 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| GB0208104D0 (en) | 2002-04-09 | 2002-05-22 | Univ Dundee | Method |
| US8030461B2 (en) | 2002-04-15 | 2011-10-04 | Chugai Seiyaku Kabushiki Kaisha | Methods for constructing scDb libraries |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20040047858A1 (en) | 2002-09-11 | 2004-03-11 | Blumberg Richard S. | Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| GB0305702D0 (en) | 2003-03-12 | 2003-04-16 | Univ Birmingham | Bispecific antibodies |
| JP2006526408A (ja) | 2003-04-22 | 2006-11-24 | アイビーシー、ファーマシューティカルズ | 多価タンパク質複合体 |
| KR20060052681A (ko) | 2003-05-23 | 2006-05-19 | 와이어쓰 | Ｇｉｔｒ 리간드, ｇｉｔｒ 리간드-연관 분자, 항체 및그의 용도 |
| NZ544924A (en) | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
| EP1638510B1 (en) | 2003-07-01 | 2015-09-02 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| EP1660126A1 (en) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
| US7696322B2 (en) | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
| ES2458636T3 (es) | 2003-08-18 | 2014-05-06 | Medimmune, Llc | Humanización de anticuerpos |
| WO2005019429A2 (en) | 2003-08-22 | 2005-03-03 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
| AU2004280333A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Llc | Humanization of antibodies |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
| EP1692318A4 (en) | 2003-12-02 | 2008-04-02 | Genzyme Corp | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER |
| WO2005062916A2 (en) | 2003-12-22 | 2005-07-14 | Centocor, Inc. | Methods for generating multimeric molecules |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| US8383575B2 (en) | 2004-01-30 | 2013-02-26 | Paul Scherrer Institut | (DI)barnase-barstar complexes |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| EP2295588B1 (en) | 2004-05-27 | 2018-03-07 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses thefor |
| US20060002932A1 (en) | 2004-06-04 | 2006-01-05 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
| US20060204493A1 (en) | 2004-09-02 | 2006-09-14 | Genentech, Inc. | Heteromultimeric molecules |
| WO2006036445A2 (en) | 2004-09-24 | 2006-04-06 | Trustees Of Dartmouth College | Chimeric nk receptor and methods for treating cancer |
| EP3530321A1 (en) | 2004-12-10 | 2019-08-28 | Peter MacCallum Cancer Institute | Methods and compositions for adoptive immunotherapy |
| US7812135B2 (en) | 2005-03-25 | 2010-10-12 | Tolerrx, Inc. | GITR-binding antibodies |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| CN101484182B (zh) | 2005-04-06 | 2014-06-11 | Ibc药品公司 | 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途 |
| AU2006236439B2 (en) | 2005-04-15 | 2012-05-03 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| NZ563263A (en) | 2005-05-17 | 2010-04-30 | Univ Connecticut | Composition and methods for immunomodulation in an organism |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US20060263367A1 (en) | 2005-05-23 | 2006-11-23 | Fey Georg H | Bispecific antibody devoid of Fc region and method of treatment using same |
| AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| NZ612578A (en) | 2005-08-19 | 2014-11-28 | Abbvie Inc | Dual variable domain immunoglobin and uses thereof |
| EP1757622B1 (en) | 2005-08-26 | 2009-12-23 | PLS Design GmbH | Bivalent IgY antibody constructs for diagnostic and therapeutic applications |
| WO2007044729A2 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| WO2007044887A2 (en) | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Method for producing a population of homogenous tetravalent bispecific antibodies |
| WO2007062466A1 (en) | 2005-11-29 | 2007-06-07 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
| HUE037464T2 (hu) | 2005-12-02 | 2018-08-28 | Icahn School Med Mount Sinai | Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk |
| CA2636111C (en) | 2006-01-13 | 2018-04-03 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells |
| WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
| MX2008010561A (es) | 2006-02-15 | 2009-03-02 | Imclone Systems Inc | Anticuerpos funcionales. |
| US7951918B2 (en) | 2006-03-17 | 2011-05-31 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| WO2007112362A2 (en) | 2006-03-24 | 2007-10-04 | The Regents Of The University Of California | Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition |
| AR060070A1 (es) | 2006-03-24 | 2008-05-21 | Merck Patent Gmbh | Dominios proteicos heterodimericos obtenidos por ingenieria |
| US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
| US8501185B2 (en) | 2006-05-25 | 2013-08-06 | Bayer Healthcare Llc | Dimeric molecular complexes |
| US20070274985A1 (en) | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
| EP3805269A1 (en) | 2006-06-12 | 2021-04-14 | Aptevo Research and Development LLC | Single-chain multivalent binding proteins with effector function |
| US7741446B2 (en) | 2006-08-18 | 2010-06-22 | Armagen Technologies, Inc. | Fusion antibodies that cross the blood-brain barrier in both directions |
| PL2059533T3 (pl) | 2006-08-30 | 2013-04-30 | Genentech Inc | Przeciwciała wieloswoiste |
| US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| CN101965363A (zh) | 2006-11-02 | 2011-02-02 | 丹尼尔·J·卡鹏 | 具有活动部分的杂合免疫球蛋白 |
| US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
| US20100178684A1 (en) | 2006-12-21 | 2010-07-15 | Woo Savio L C | Transgenic oncolytic viruses and uses thereof |
| ES2593484T3 (es) | 2007-03-29 | 2016-12-09 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| EP2537416B1 (en) | 2007-03-30 | 2014-11-12 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| US8163279B2 (en) | 2007-04-13 | 2012-04-24 | Stemline Therapeutics, Inc. | IL3Rα antibody conjugates and uses thereof |
| CA2682605A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
| EP2724727A1 (en) | 2007-06-27 | 2014-04-30 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Complexes of IL-15 and IL-15R alpha and uses thereof |
| EP2175884B8 (en) | 2007-07-12 | 2017-02-22 | GITR, Inc. | Combination therapies employing gitr binding molecules |
| EP2626371A1 (en) | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
| ES2628395T3 (es) | 2007-08-15 | 2017-08-02 | Bayer Pharma Aktiengesellschaft | Anticuerpo regulado por proteasa |
| US9416165B2 (en) | 2007-10-26 | 2016-08-16 | The Regents Of The University Of California | Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors |
| KR20100097716A (ko) | 2007-11-27 | 2010-09-03 | 아블린쓰 엔.브이. | 이종이량체 사이토킨 및/또는 이의 수용체에 대한 아미노산 서열과 이를 포함하는 폴리펩티드 |
| GB2468232B (en) | 2007-11-30 | 2012-10-24 | Glaxo Group Ltd | Antigen-bindng constructs |
| CA2706337A1 (en) | 2007-12-06 | 2009-06-11 | Csl Limited | Method of inhibition of leukemic stem cells |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
| WO2009097140A1 (en) | 2008-01-30 | 2009-08-06 | Memorial Sloan-Kettering Cancer Center | Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors |
| EP2242773B1 (en) | 2008-02-11 | 2017-06-14 | Cure Tech Ltd. | Monoclonal antibodies for tumor treatment |
| JP2011512395A (ja) | 2008-02-21 | 2011-04-21 | アストラゼネカ アクチボラグ | 組合せ療法２３８ |
| US8379824B2 (en) | 2008-03-06 | 2013-02-19 | At&T Intellectual Property I, Lp | Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| KR20110044992A (ko) | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | ＴＧＦ-β 길항제 다중-표적 결합 단백질 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| HUE027525T2 (en) | 2008-08-25 | 2016-11-28 | Amplimmune Inc | PD-1 Antagonist preparations and their use |
| MX2011002250A (es) | 2008-08-25 | 2011-08-17 | Amplimmune Inc | Antagonistas de muerte celular programada-1 y métodos de uso de los mismos. |
| US8822647B2 (en) | 2008-08-26 | 2014-09-02 | City Of Hope | Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells |
| CN102149820B (zh) | 2008-09-12 | 2014-07-23 | 国立大学法人三重大学 | 能够表达外源gitr配体的细胞 |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| PT2376535T (pt) | 2008-12-09 | 2017-06-23 | Hoffmann La Roche | Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t |
| US9206440B2 (en) | 2009-01-23 | 2015-12-08 | Roger Williams Hospital | Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same |
| ES2550179T3 (es) | 2009-02-05 | 2015-11-05 | Icahn School Of Medicine At Mount Sinai | Virus quiméricos de la enfermedad de Newcastle y usos de los mismos |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| WO2010110346A1 (ja) | 2009-03-24 | 2010-09-30 | 独立行政法人理化学研究所 | 白血病幹細胞マーカー |
| CN102428085B (zh) | 2009-04-03 | 2015-07-15 | 维拉斯通股份有限公司 | 作为激酶抑制剂的嘧啶取代的嘌呤化合物 |
| EP2426148B1 (en) | 2009-04-27 | 2015-08-05 | Kyowa Hakko Kirin Co., Ltd. | Anti-il-3ra antibody for use in treatment of blood tumor |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| US8598322B2 (en) | 2009-04-30 | 2013-12-03 | Tel Hashomer Medical Research Infrastucture and Services Ltd. | Anti CEACAM1 antibodies and methods of using same |
| AU2010282280B2 (en) | 2009-08-14 | 2016-06-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of IL-15 to increase thymic output and to treat lymphopenia |
| HUE049825T2 (hu) | 2009-09-03 | 2020-10-28 | Merck Sharp & Dohme | Anti-GITR antitestek |
| WO2011041093A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| EP2470212A4 (en) | 2009-10-01 | 2013-12-04 | Csl Ltd | METHOD FOR TREATING POSITIVE PHILADELPHIA CHROMOSOME LEUKEMIA |
| US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
| SI2496698T1 (sl) | 2009-11-03 | 2019-07-31 | City Of Hope | Skrajšan epiderimalni receptor faktorja rasti (EGFRt) za selekcijo transduciranih T celic |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| EP2332994A1 (en) | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| JP5851419B2 (ja) | 2009-12-29 | 2016-02-03 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ヘテロダイマー結合タンパク質およびその使用 |
| WO2011097477A1 (en) | 2010-02-04 | 2011-08-11 | The Trustees Of The University Of Pennsylvania | Icos critically regulates the expansion and function of inflammatory human th17 cells |
| EP4477668A3 (en) | 2010-04-20 | 2025-03-19 | Genmab A/S | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| PL2582390T3 (pl) | 2010-06-15 | 2015-05-29 | Csl Ltd | Sposób immunoterapeutyczny obejmujący przeciwciała przeciwko CD123 (IL-3R) oraz kompleks immunostymulacyjny |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| AR084469A1 (es) | 2010-07-09 | 2013-05-22 | Exelixis Inc | Combinaciones de inhibidores de quinasas para el tratamiento del cancer |
| MX2013000617A (es) | 2010-07-16 | 2013-06-13 | Piramal Entpr Ltd | Derivados sustituidos de imidazoquinolina como inhibidores de quinasa. |
| WO2012012667A2 (en) | 2010-07-21 | 2012-01-26 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a hla locus |
| US9493740B2 (en) | 2010-09-08 | 2016-11-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered GD2-specific T cells |
| NZ706016A (en) | 2010-10-27 | 2016-10-28 | Baylor College Medicine | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3693017A1 (en) | 2010-12-14 | 2020-08-12 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| CN103442768A (zh) | 2011-01-18 | 2013-12-11 | 宾夕法尼亚大学董事会 | 治疗癌的组合物和方法 |
| WO2012127464A2 (en) | 2011-03-23 | 2012-09-27 | Gavish-Galilee Bio Applications Ltd | Constitutively activated t cells for use in adoptive cell therapy |
| BR112013024395B1 (pt) | 2011-03-23 | 2021-10-26 | Fred Hutchinson Cancer Research Center | Composições adotivas de imunoterapia celular e método para fabricação da dita composição |
| EA201391449A1 (ru) | 2011-04-01 | 2014-03-31 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Антитела против пептидов цитозоля |
| MX347656B (es) | 2011-04-08 | 2017-05-08 | Baylor College Medicine | Inversion de los efectos del micro-ambiente de tumor utilizando receptores de citocina quimericos. |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| CN102796198A (zh) | 2011-05-26 | 2012-11-28 | 中国医学科学院血液病医院 | 抗CD3抗体Fv片段与白介素3的融合蛋白、制备方法及其用途 |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| EP4488370A2 (en) | 2011-07-25 | 2025-01-08 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expresssion of dux4 |
| ES2888651T3 (es) | 2011-07-29 | 2022-01-05 | Univ Pennsylvania | Receptores de conmutación coestimulantes |
| MY186267A (en) | 2011-08-11 | 2021-07-01 | Intellikine Llc | Kinase inhibitor polymorphs |
| WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
| EP3692794A1 (en) | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| SG11201400527XA (en) | 2011-09-16 | 2014-04-28 | Univ Pennsylvania | Rna engineered t cells for the treatment of cancer |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| AU2012325915A1 (en) | 2011-10-20 | 2014-04-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD22 chimeric antigen receptors |
| WO2013060867A2 (en) | 2011-10-27 | 2013-05-02 | Genmab A/S | Production of heterodimeric proteins |
| US9556271B2 (en) | 2011-12-01 | 2017-01-31 | The Brigham And Women's Hospital, Inc. | Anti-CEACAM1 recombinant antibodies for cancer therapy |
| US9718893B2 (en) | 2011-12-19 | 2017-08-01 | Synimmune Gmbh | Bispecific antibody molecule |
| AU2013222288A1 (en) | 2012-02-22 | 2014-08-14 | The Trustees Of The University Of Pennsylvania | Use of ICOS-based CARs to enhance antitumor activity and CAR persistence |
| US10040846B2 (en) | 2012-02-22 | 2018-08-07 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer |
| CN104136458A (zh) | 2012-02-22 | 2014-11-05 | 宾夕法尼亚大学董事会 | 在第二代嵌合抗原受体中cd2信号传导结构域的使用 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| HUE059815T2 (hu) | 2012-05-18 | 2022-12-28 | Aptevo Res & Development Llc | Bispecifikus SCFV immunofuziós (BIF) kötõdés a CD123-hoz és a CD3-hoz |
| EP4570908A3 (en) | 2012-05-25 | 2025-10-22 | The Regents of the University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| EA201992742A3 (ru) | 2012-07-13 | 2020-12-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Применение cart19 для истощения нормальных b-клеток для индукции толерантности |
| ES2941370T3 (es) | 2012-07-13 | 2023-05-22 | Univ Pennsylvania | Control de la toxicidad para la actividad antitumoral de los CAR |
| IN2014DN11156A (enExample) | 2012-07-13 | 2015-10-02 | Univ Pennsylvania | |
| MX2015000426A (es) | 2012-07-13 | 2015-07-14 | Univ Pennsylvania | Incremento de actividad de celulas t car mediante cointroduccion de un anticuerpo biespecifico. |
| CA2878856A1 (en) | 2012-07-13 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulating car t cells |
| US20160235787A1 (en) | 2012-07-13 | 2016-08-18 | The Trustees Of The University Of Pennsylvania | Epitope Spreading Associated with CAR T-Cells |
| EP2879709B1 (en) | 2012-07-31 | 2020-01-08 | The Brigham and Women's Hospital, Inc. | Modulation of the immune response |
| DK3824905T3 (da) | 2012-08-20 | 2025-03-17 | Fred Hutchinson Cancer Center | Fremgangsmåde og sammensætninger til cellulær immunterapi |
| WO2014039513A2 (en) | 2012-09-04 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive t cell transfer |
| TW201414837A (zh) | 2012-10-01 | 2014-04-16 | Univ Pennsylvania | 標定基質細胞以治療癌症之組合物和方法 |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US9597357B2 (en) * | 2012-10-10 | 2017-03-21 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
| EP3679950A1 (en) | 2012-10-12 | 2020-07-15 | The Brigham and Women's Hospital, Inc. | Enhancement of the immune response |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2014093595A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
| DK3064585T3 (da) | 2012-12-12 | 2020-04-27 | Broad Inst Inc | Konstruering og optimering af forbedrede systemer, fremgangsmåder og enzymsammensætninger til sekvensmanipulation |
| US20160008399A1 (en) | 2013-01-14 | 2016-01-14 | Fred Hutchinson Cancer Research Center | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse |
| MX374929B (es) | 2013-02-20 | 2025-03-06 | Novartis Ag | RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO. |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| WO2014138819A1 (en) | 2013-03-14 | 2014-09-18 | Csl Limited | Agents that neutralize il-3 signaling and uses thereof |
| WO2014138805A1 (en) | 2013-03-14 | 2014-09-18 | Csl Limited | Anti il-3r alpha agents and uses thereof |
| WO2014158811A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| EP3004168A4 (en) | 2013-05-24 | 2017-03-01 | Board of Regents, The University of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| ES2779123T3 (es) | 2013-09-26 | 2020-08-13 | Ablynx Nv | Nanobodies biespecíficos |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| US10640569B2 (en) | 2013-12-19 | 2020-05-05 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| WO2015105522A1 (en) * | 2014-01-13 | 2015-07-16 | Forman Stephen J | Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use |
| EP4303229A3 (en) | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| JP6665102B2 (ja) | 2014-02-21 | 2020-03-13 | セレクティスＣｅｌｌｅｃｔｉｓ | 制御性ｔ細胞をインサイチューで阻害するための方法 |
| ES2939760T3 (es) | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
| WO2015142661A1 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
| TR201910814T4 (tr) | 2014-03-19 | 2019-08-21 | Cellectis | Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri. |
| HUE054588T2 (hu) | 2014-04-07 | 2021-09-28 | Novartis Ag | Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával |
| US9777061B2 (en) | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| US20170274014A1 (en) | 2014-07-21 | 2017-09-28 | Jennifer Brogdon | Combinations of low, immune enhancing, doses of mtor inhibitors and cars |
| KR102612313B1 (ko) | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
| EP3194585A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Sortase molecules and uses thereof |
| CN107109420A (zh) | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | 使用cll－1嵌合抗原受体的癌症治疗 |
| EP3174546B1 (en) | 2014-07-31 | 2019-10-30 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
| JP6919118B2 (ja) | 2014-08-14 | 2021-08-18 | ノバルティス アーゲー | ＧＦＲα−４キメラ抗原受容体を用いる癌の治療 |
| PL3183268T3 (pl) | 2014-08-19 | 2020-09-07 | Novartis Ag | Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego |
| WO2016044605A1 (en) | 2014-09-17 | 2016-03-24 | Beatty, Gregory | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| WO2016057705A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| WO2016061368A1 (en) | 2014-10-15 | 2016-04-21 | The Children's Hospital Of Philadelphia | Compositions and methods for treating b-lymphoid malignancies |
| CA2972597A1 (en) | 2014-12-29 | 2016-07-07 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| CN119925616A (zh) | 2015-04-08 | 2025-05-06 | 诺华股份有限公司 | Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法 |
| ES2948133T3 (es) | 2015-04-17 | 2023-08-31 | Novartis Ag | Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico |
| US12128069B2 (en) | 2015-04-23 | 2024-10-29 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| TWI859112B (zh) | 2015-07-21 | 2024-10-21 | 瑞士商諾華公司 | 改良免疫細胞之功效及擴展之方法 |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| JP6905163B2 (ja) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
| BR112018005295A2 (pt) | 2015-09-17 | 2018-12-11 | Novartis Ag | terapias com célula t car com eficácia aumentada |
| CN109069597A (zh) | 2015-12-22 | 2018-12-21 | 诺华股份有限公司 | 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗 |
| MX2018008106A (es) | 2015-12-30 | 2019-03-14 | Novartis Ag | Terapias con celulas inmunoefectoras de una eficacia mejorada. |
| EP3423482A1 (en) | 2016-03-04 | 2019-01-09 | Novartis AG | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
| EP3464375A2 (en) | 2016-06-02 | 2019-04-10 | Novartis AG | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
| AU2017295886C1 (en) | 2016-07-15 | 2024-05-16 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| TW202508628A (zh) | 2016-07-28 | 2025-03-01 | 瑞士商諾華公司 | 嵌合抗原受體及pd-1抑制劑之組合療法 |
| RU2019105693A (ru) | 2016-08-01 | 2020-09-01 | Новартис Аг | Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага |
| CN110582488A (zh) | 2016-09-30 | 2019-12-17 | 诺华股份有限公司 | 具有增强功效的免疫效应细胞疗法 |
| EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
| US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| US20200048359A1 (en) | 2017-02-28 | 2020-02-13 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| BR112019019426A2 (pt) | 2017-03-22 | 2020-05-26 | Novartis Ag | Biomarcadores e terapias com células t car com eficácia intensificada |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| SG11202003415XA (en) | 2017-10-18 | 2020-05-28 | Novartis Ag | Compositions and methods for selective protein degradation |
| KR20200069358A (ko) | 2017-10-25 | 2020-06-16 | 노파르티스 아게 | 키메라 항원 수용체 발현 세포의 제조 방법 |
| RU2020119365A (ru) | 2017-11-15 | 2021-12-13 | Новартис Аг | Химерный антигенный рецептор, нацеливающийся на всма, химерный антигенный рецептор, нацеливающийся на cd19, и средства комбинированной терапии |
| MX2020005651A (es) | 2017-11-30 | 2020-10-28 | Novartis Ag | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. |
| EP3752203A1 (en) | 2018-02-13 | 2020-12-23 | Novartis AG | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| US20200061113A1 (en) | 2018-04-12 | 2020-02-27 | Novartis Ag | Chimeric antigen receptor therapy characterization assays and uses thereof |
| US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| US20200085869A1 (en) | 2018-05-16 | 2020-03-19 | Novartis Ag | Therapeutic regimens for chimeric antigen receptor therapies |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| CA3100724A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof |
| EP3844265A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| EP3856782A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
| WO2020069405A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
| CA3126087A1 (en) | 2019-02-25 | 2020-09-03 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| IL293215A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors that bind bcma and cd19 and their uses |
| AU2020394441B2 (en) | 2019-11-26 | 2025-11-13 | Novartis Ag | CD19 and CD22 chimeric antigen receptors and uses thereof |
-
2015
- 2015-08-19 PL PL15756525T patent/PL3183268T3/pl unknown
- 2015-08-19 EP EP15756525.0A patent/EP3183268B1/en active Active
- 2015-08-19 ES ES15756525T patent/ES2791248T3/es active Active
- 2015-08-19 RU RU2020117196A patent/RU2020117196A/ru unknown
- 2015-08-19 AU AU2015305531A patent/AU2015305531B2/en active Active
- 2015-08-19 EP EP19219069.2A patent/EP3712171A1/en not_active Withdrawn
- 2015-08-19 PT PT157565250T patent/PT3183268T/pt unknown
- 2015-08-19 MX MX2017002205A patent/MX2017002205A/es unknown
- 2015-08-19 CN CN201580056515.6A patent/CN107108744B/zh active Active
- 2015-08-19 RU RU2017108903A patent/RU2724999C2/ru active
- 2015-08-19 LT LTEP15756525.0T patent/LT3183268T/lt unknown
- 2015-08-19 SG SG11201700770PA patent/SG11201700770PA/en unknown
- 2015-08-19 HU HUE15756525A patent/HUE049218T2/hu unknown
- 2015-08-19 DK DK15756525.0T patent/DK3183268T3/da active
- 2015-08-19 JP JP2017509621A patent/JP7084138B2/ja active Active
- 2015-08-19 TW TW104127072A patent/TWI719946B/zh active
- 2015-08-19 WO PCT/US2015/045898 patent/WO2016028896A1/en not_active Ceased
- 2015-08-19 US US14/830,392 patent/US9815901B2/en active Active
- 2015-08-19 MY MYPI2017700355A patent/MY189028A/en unknown
- 2015-08-19 CA CA2958553A patent/CA2958553A1/en active Pending
- 2015-08-19 CN CN202010892861.0A patent/CN112410363A/zh active Pending
- 2015-08-19 KR KR1020177007130A patent/KR102616429B1/ko active Active
- 2015-08-19 TW TW110102298A patent/TW202140557A/zh unknown
-
2017
- 2017-01-30 IL IL250362A patent/IL250362B/en active IP Right Grant
- 2017-02-17 CO CONC2017/0001573A patent/CO2017001573A2/es unknown
- 2017-10-06 US US15/726,703 patent/US10703819B2/en active Active
-
2020
- 2020-05-27 US US16/884,867 patent/US11591404B2/en active Active
-
2021
- 2021-01-14 IL IL280204A patent/IL280204A/en unknown
- 2021-07-26 JP JP2021121574A patent/JP2021184715A/ja active Pending
- 2021-08-20 AU AU2021218185A patent/AU2021218185A1/en not_active Abandoned
-
2022
- 2022-12-30 US US18/148,807 patent/US20230220090A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530694A5 (enExample) | ||
| JPWO2016028896A5 (enExample) | ||
| RU2017108903A (ru) | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей | |
| US20250215096A1 (en) | Chimeric antigen receptor therapy in combination with il-15r and il15 | |
| US20240075070A1 (en) | Chimeric antigen receptor t cells targeting the tumor microenvironment | |
| JP2017522879A5 (enExample) | ||
| JP2017527271A5 (enExample) | ||
| JP7303749B2 (ja) | Ｔｉｍ－１を標的とするキメラ抗原受容体 | |
| RU2017105160A (ru) | Лечение рака с помощью химерного антигенного рецептора к cd33 | |
| JP2025032091A5 (enExample) | ||
| RU2017105161A (ru) | Лечение рака с использованием химерного антигенного рецептора cll-1 | |
| JP2017522880A5 (enExample) | ||
| US12161668B2 (en) | T cells expressing a chimeric antigen receptor | |
| RU2017105065A (ru) | Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма | |
| JP2019523301A5 (enExample) | ||
| JP2017524367A5 (enExample) | ||
| JP2018518939A5 (enExample) | ||
| JP2018538339A5 (enExample) | ||
| US20220184127A1 (en) | Humanized anti-dll3 chimeric antigen receptors and uses thereof | |
| US20220184126A1 (en) | Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof | |
| JP7524465B2 (ja) | 免疫細胞機能の改善 | |
| EP4114924A1 (en) | Gamma delta t cells and uses thereof | |
| JP2022554353A (ja) | Ｔ細胞療法と（ｓ）－３－［４－（４－モルホリン－４－イルメチル－ベンジルオキシ）－１－オキソ－１，３－ジヒドロ－イソインドール－２－イル］－ピペリジン－２，６－ジオンとの併用 | |
| WO2025255180A1 (en) | Combination therapy using cell immunotherapy and an anti-cancer agent for treating cancer | |
| WO2023154626A2 (en) | Anti-il13ra2 antibodies and uses thereof |